Skip to content
Upperton Pharma Solutions white logo
  • Services
    • Pre-formulation Studies
      • UpperSolv™
      • PulmoCraft™
    • Formulation Development
    • Clinical Manufacturing
    • Analytical Services
  • Expertise
    • Spray Drying
    • Oral Dosage Forms
    • Inhalation Delivery
    • Virtual Seminars
  • About
  • News
  • Contact Us

News

Upcoming Events

No posts found.

Press Releases

29th April 2020 – Upperton Invest £500K in their Tablet Formulation and Manufacturing Capabilities

10th December 2019 – Upperton is Launching an Enabling Technology Screening Protocol – UpperSolv™

29th October 2019 – Upperton continues to invest in key equipment to support expansion of its solid dosage form capabilities and CDMO Services

17th September 2019 – Upperton Pharma Solutions Investment Increases Tabletting Capabilities

8th January 2019 – MHRA Inspection success for Nottingham’s Upperton Pharma Solutions

Published Papers

New GMP Manufacturing Processes to Obtain Thermostable HIV-1 gp41 Virosomes Under Solid Forms for Various Mucosal Vaccination Routes

Upperton Articles

9th May 2019 – Developing Oral Dosage Forms for Clinical Trials

15th April 2019 – Spray Drying Process Development and Scale up

19th March 2019 – Engineered Powders for Enhanced Pulmonary Delivery

5th March 2019 – Analytical Techniques for Biotherapeutics

19th February 2019 – Biotherapeutic Formulation Development

5th February 2019 – Extended Capabilities on Upperton’s non-GMP Pilot Plant

22nd January 2019 – Successful completion of EU Horizon 2020 Grant MACIVIVA

  • ‹
  • 1
  • 2
  • 3
Loading...

Can we help you?

Contact Us
  • Home
  • Services
  • Expertise
  • About
  • News
  • Contact
  • Careers
  • Privacy Policy
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN| Phone: +44 (0) 115 855 7050 | Email: contact@upperton.com
Copyright © 2021 Upperton Pharma Solutions
Scroll to Top
Upperton use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy